Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane review of randomised trials of insulin-sensitising agents including D-chiro-inositol versus placebo, no treatment or ovulation-induction agents in women with PCOS and subfertility.
Key Findings
Evidence for D-chiro-inositol on reproductive outcomes in PCOS subfertility was very low quality and insufficient to demonstrate benefit for live birth.
Conclusions
Insulin-sensitising agents show uncertain reproductive benefit; inositol data in this review were too weak to support routine use.
Limitations
Very low certainty; sparse inositol-specific data; heterogeneous comparators.
Supplements Studied
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Cochrane/academic
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.